Serum zinc as a factor predicting response to interferon-α2b therapy in children with chronic hepatitis B

Biological Trace Element Research

Volumn 90, Issue 1-3, 2002, Pages 31-38

  Özbal, Ebru ^a   Helvaci, Mehmet ^a   Kasirga, Erhun ^b   Akdenizoǧlu, Figen ^a   Kizilgüneşler, Asli ^a  

^a SSK Tepecik Teaching Hospital   (Turkey)

^b CELAL BAYAR UNIVERSITY MEDICAL FACULTY   (Turkey)

Author keywords

Children; Hepatitis B virus; Interferon; Predictive factor; Zinc

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA2B INTERFERON; ZINC;

ADOLESCENT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBIOTIC RESISTANCE; ARTICLE; CELLULAR IMMUNITY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DNA VIRUS; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN TISSUE; LIVER FIBROSIS; LIVER FUNCTION; LIVER HISTOLOGY; LIVER NECROSIS; MALE; PREDICTION; SCORING SYSTEM; TREATMENT OUTCOME; ZINC BLOOD LEVEL;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; FEMALE; HEPATITIS B, CHRONIC; HUMANS; INTERFERON ALFA-2B; LIVER CIRRHOSIS; MALE; TIME FACTORS; TREATMENT OUTCOME; ZINC;

DNA VIRUSES; HEPATITIS B VIRUS;

EID: 0036961933     PISSN: 01634984     EISSN: None     Source Type: Journal    
DOI: 10.1385/BTER:90:1-3:31     Document Type: Article

References (21)

1. M. K. Maini and A. Bertoletti, How can the cellular immune response control hepatitis B virus replication? J. Viral Hepat. 7(5), 321-326 (2000).
2. P. Jara and F. Bortolotti, Interferon-alpha treatment of chronic hepatitis B in childhood: a consensus advice based on experience in European children, J. Pediatr. Gastrointerol. Nutr. 29(2), 163-170 (1999).
3. E. M. Sokal, H. S. Conjeevaram, E. A. Roberts, F. Alvarez, E. M. Bern, P. Goyens, et al., Interferon alfa therapy for chronic hepatitis B in children: a multinational randomized controlled trial, Gastroenterology 114(5), 988-995 (1998).
4. M. Pignatelli, J. Waters, D. Brown, A. Lever, S. Iwarson, Z. Schaff, et al., HLA class I antigens of the hepatocyte membrane during recovery from acute hepatitis B infection and during interferon therapy in chronic hepatitis B virus infection, Hepatology 6(3), 349-353 (1986).
5. A. H. Shankar and A. S. Prasad, Zinc and immune function: the biological basis of altered resistance to infection, Am. J. Clin. Nutr. 68(2 Suppl), 447S-463S (1998).
6. P. J. Fraker, L. E. King, T. Laakko, and T. L. Vollmer, The dynamic link between the integrity of the immune system and zinc status, J. Nutr. 130(5S Suppl.), 1399S-1406S (2000).
7. F. W. Beck, J. Kaplan, N. Fine, W. Handschu, and A. S. Prasad, Decreased expression of CD73 (ecto-5′-nucleotidase) in the CD8+ subset is associated with zinc deficiency in human patients, J. Lab. Clin. Med. 130(2), 147-156 (1997).
8. L. Rink, and H. Kirchner, Zinc-altered immune function and cytokine production, J. Nutr. 130(5S Suppl.), 1407S-1411S (2000).
9. H. H. Sandstead, Zinc deficiency. A public health problem? Am. J. Dis. Child. 145(8), 853-859 (1991).
10. L. H. Allen, Zinc and micronutrient supplements for children, Am. J. Clin. Nutr. 68(2 Suppl.), 495S-498S (1998).
11. V. J. Desmet, M. Gerber, J. H. Hoofnagle, M. Manns, and P. J. Scheuer, Classification of chronic hepatitis: diagnosis, grading and staging, Hepatology 19(6), 1513-1520 (1994).
12. K. H. Brown, Effect of infections on plasma zinc concentration and implications for zinc status assessment in low-income countries. Am. J. Nutr. 68(2 Suppl.), 425S-429S (1998).
13. C. Pramoolsinsap, N. Promvanit, S. Komindr, P. Lerdverasirikul, and S. Srianujata, Serum trace metals in chronic viral hepatitis and hepatocellular carcinoma in Thailand, J. Gastroenterol. 29(5), 610-615 (1994).
14. D. R. Milich, F. Schodel, D. L. Peterson, J. E. Jones, and J. L. Hughes, Characterization of self-reactive T cells that evade tolerance in hepatitis B e antigen transgenic mice. Eur. J. Immunol. 25(6), 1663-1672 (1995).
15. E. Mocchegiani and M. Muzzioli, Therapeutic application of zinc in human immunodeficiency virus against opportunistic infections. J. Nutr. 130(5S Suppl.), 1424S-1431S (2000).
16. S. Goodbourn, L. Didcock, and R. E. Randall, Interferons: cell signalling, immune modulation, antiviral response and virus countermeasures, J. Gen. Virol. 81(Pt. 10), 2341-2364 (2000).
17. R. Radhakrishnan, L. J. Walter, A. Hruza, P. Reichert, P. P. Trotta, T. L. Nagabhushan, et al. Zinc mediated dimer of human interferon-alpha 2b revealed by X-ray crystallography, Structure 4(12), 1453-1463 (1996).
18. M. A. Selimoglu, S. Aydogdu, F. Unal, G. Yuce, and R. V. Yagci, Serum zinc status in chronic hepatitis B and its relationship to liver histology and treatment results. Pediatr. Int. 43(4), 396-399 (2001).
19. M. Ruiz-Moreno, T. Camps, J. Jimenez, R. Lopez, I. Castillo, J. Bartolome, et al., Factors predictive of response to interferon therapy in children with chronic hepatitis B, J. Hepatol. 22(5), 540-544 (1995).
20. E. Mocchegiani, M. Muzzioli, and R. Giacconi, Zinc and immunoresistance to infection in aging: new biological tools, Trends Pharmacol. Sci. 21(6), 205-208 (2000).
21. H. Takagi, T. Nagamine, T. Abe, H. Takayama, K. Sato, T. Otsuka, et al. Zinc supplementation enhances the response to interferon therapy in patients with chronic hepatitis C, J. Viral Hepat. 8(5), 367-371 (2001).